[go: up one dir, main page]

WO2003037309A3 - USE OF 4α PHORBOL - Google Patents

USE OF 4α PHORBOL Download PDF

Info

Publication number
WO2003037309A3
WO2003037309A3 PCT/GB2002/004911 GB0204911W WO03037309A3 WO 2003037309 A3 WO2003037309 A3 WO 2003037309A3 GB 0204911 W GB0204911 W GB 0204911W WO 03037309 A3 WO03037309 A3 WO 03037309A3
Authority
WO
WIPO (PCT)
Prior art keywords
phorbol
bronchiectasis
young
syndrome
maintaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/004911
Other languages
French (fr)
Other versions
WO2003037309A2 (en
Inventor
Anil Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Priority to AU2002349103A priority Critical patent/AU2002349103A1/en
Publication of WO2003037309A2 publication Critical patent/WO2003037309A2/en
Publication of WO2003037309A3 publication Critical patent/WO2003037309A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of 4α phorbol in maintaining or enhancing ciliary beat frequency such as in the treatment of subjects suffering from diseases associated with reduced or poor mucociliary clearance, such as cystic fibrosis, primary cilia dyskinesia, Young's syndrome or bronchiectasis.
PCT/GB2002/004911 2001-10-30 2002-10-29 USE OF 4α PHORBOL Ceased WO2003037309A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002349103A AU2002349103A1 (en) 2001-10-30 2002-10-29 Use of 4alpha phorbol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0126000A GB0126000D0 (en) 2001-10-30 2001-10-30 Use of 4ñ Phorbol
GB0126000.9 2001-10-30

Publications (2)

Publication Number Publication Date
WO2003037309A2 WO2003037309A2 (en) 2003-05-08
WO2003037309A3 true WO2003037309A3 (en) 2003-06-05

Family

ID=9924770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004911 Ceased WO2003037309A2 (en) 2001-10-30 2002-10-29 USE OF 4α PHORBOL

Country Status (3)

Country Link
AU (1) AU2002349103A1 (en)
GB (1) GB0126000D0 (en)
WO (1) WO2003037309A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268148B2 (en) 2005-07-13 2012-11-01 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716179A (en) * 1979-01-23 1987-12-29 Stiftung Deutches Krebsforschungszentrum Use of non-irritating or slightly irritating and/or promoting diterpene alcohol and of derivatives thereof as antineoplastic preparations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716179A (en) * 1979-01-23 1987-12-29 Stiftung Deutches Krebsforschungszentrum Use of non-irritating or slightly irritating and/or promoting diterpene alcohol and of derivatives thereof as antineoplastic preparations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HERMELIN B ET AL: "PHORBOL ESTER-INDUCED PROTEIN KINASE C TRANSLOCATION AND LYSOSOMAL ENZYME RELEASE IN NORMAL AND CYSTIC FIBROSIS FIBROBLASTS", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 229, no. 1, February 1988 (1988-02-01), pages 161 - 166, XP001148360, ISSN: 0014-5793 *
MWIMBI X K M S ET AL: "4alpha-Phorbol negates the inhibitory effects of phorbol-12-myristate-13-acetate on human cilia and alters the phosphorylation of PKC", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 530, no. 1-3, 23 October 2002 (2002-10-23), pages 31 - 36, XP004388086, ISSN: 0014-5793 *
SALATHE M ET AL: "Detectable phosphorylation changes in sheep airway cilia isolated from small tissue pieces after treatment with PMA and hydrogen peroxide.", MOLECULAR BIOLOGY OF THE CELL, vol. 3, no. SUPPL., 1992, Thirty-second Annual Meeting of the American Society for Cell Biology, Denver, Colorado, USA, November 15-19, 1992. MOL BIOL CELL, pages 170A, XP000801442, ISSN: 1059-1524 *

Also Published As

Publication number Publication date
AU2002349103A1 (en) 2003-05-12
GB0126000D0 (en) 2001-12-19
WO2003037309A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
AU1122202A (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
AU4671101A (en) Formulation for the prevention of cardiovascular disease
NO993776L (en) Certain dinucleotides and their use as modulators of mucociliary purification and cilia shock frequency
WO1999014346A3 (en) SENSE mRNA THERAPY
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2002100442A3 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
CA2474511A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
WO2002016369A3 (en) Novel macrocycles and uses thereof
WO2002070464A3 (en) Hydrazones and their therapeutic use
WO2002083167A3 (en) Therapeutic compositions for the treatment of a respiratory tract disease
DE60006448D1 (en) Mercapto alcohol compounds than as flavorings
AP2003002753A0 (en) Use of salmeterol and fluticasone propionate combination
CA2251132A1 (en) Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents
WO2002102318A3 (en) Eglin c based drugs for treatment of disease
WO2003037309A3 (en) USE OF 4α PHORBOL
NO984572D0 (en) Use of 2,5-dihydroxybenzenesulfone derivatives for the manufacture of drugs intended for normalization of endothelial function, for the treatment of sexual dysfunction and vascular complications in diabetes, as well as vascular disorders of
WO2002040512A3 (en) Human beta-defensin-3
WO2002072105A3 (en) Improved prostanoid therapies for the treatment of glaucoma
WO2002083700A3 (en) Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
WO1999004822A3 (en) New salts with beneficial organoleptic properties
FI964749A0 (en) Acylated enol derivatives as prodrugs of elastase inhibitors
WO2000006138A3 (en) Use of moclobemide for treating pain and other diseases
WO2002074330A3 (en) Mycobacterrial estracts for treating autoimmune diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP